Clinical Trial

Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2026 (before its estimated August 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the effects of Levodopa-Benserazide drug combination on periodontal status and salivary cytokine levels in patients with Parkinson's disease. The study includes four groups: Parkinson's patients with periodontitis, periodontally healthy Parkinson's patients, participants without Parkinson's with periodontitis, and periodontally healthy participants without Parkinson's. Clinical periodontal parameters (Plaque Index, Gingival Index, Bleeding on Probing, Pocket Depth, and Clinical Attachment Loss) will be recorded. Unstimulated saliva samples will be collected to analyze the levels of TNF-alpha, RANTES, IL-10, IL-13, Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and Malondialdehyde (MDA).
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-04-28
Trial Details
NCT Number NCT07405268
Lead Sponsor Saglik Bilimleri Universitesi
Collaborators: Hacettepe University
Conditions Parkinson Disease (PD), Periodontitis, Periodontal Diseases
Enrollment 136 participants
Start Date 2026-02-10
Primary Completion 2026-08-10 (estimated)
Study Completion 2026-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-27